SGLT2 has recently gained recognition as a potential therapeutic target for reducing hyperglycemia in T2DM, and several selective SGLT2 inhibitors are being evaluated in the clinic [16-22]. This evidence concerns the gene SLC5A2 and Hyperglycemia.